Capturing Data in Rare Disease Registries to Support Regulatory Decision Making: A Survey Study Among Industry and Other Stakeholders

Abstract

Introduction In rare diseases, registry-based studies can be used to provide natural history data pre-approval and complement drug efficacy and/or safety knowledge post-approval. Objective The objective of this study was to investigate the opinion of stakeholders about key aspects of rare disease registries that are used to support regulatory decision making and to compare the responses of employees from industry to other stakeholders. Methods A web-based survey was used to gauge the importance of (1) common data elements (including safety outcomes), (2) data quality and (3) governance aspects that are generic across different rare diseases. The survey included 47 questions. The data were collected in the period April-October 2019. Results Seventy-three respondents completed ≥ 80% of the survey. Most of the respondents were from the industry (n = 42, 57%). For safety data, 31 (42%) respondents were in favour of collecting all adverse events. For data quality, the respondents found a level of 30% reasonable for source data verification. For missing data, a level of 20% was considered acceptable. Compared to responders from industry, the other stakeholders found it less relevant to share data with industry and found it less acceptable if the registry is financed by industry. Conclusions This study showed that the opinion towards data and governance is well aligned across parties, and issues of data and governance on their own should not pose a barrier to collaboration. This finding is supportive of the European Medicines Agency's efforts to encourage stakeholders to work with existing registries when collecting data to support regulatory decision making.

Exploring Alternative Financing Models and Early Access Schemes for Orphan Drugs: a Belgian Case Study

“…An overarching precondition that frequently reoccurred in the discussions, was the importance of quality, robust and digital data collection. This nding corroborates recent survey results of encouraging stakeholders to consult registries in decision-making (53). Prior to initiating therapy with an orphan drug, a protocol with clear questions and instructions on what evidence to collect should be drafted.…”

How can a joint European health technology assessment provide an ‘additional benefit’ over the current standard of national assessments?

“…This finding is not uncommon. In a recent cross-stakeholder web-based survey on data issues in rare disease registries, supporting regulatory decision making also identified well aligned opinions of the various stakeholder groups [ 14 ]. However, ongoing integration of all these stakeholder groups within the evolving HTA landscape is critical.…”

Remodeling an existing rare disease registry to be used in regulatory context: Lessons learned and recommendations

“…The role of registries in regulatory assessment has been widely investigated and promoted by the scientific community (Hollak et al, 2015;Hollak et al, 2020) and by the EMA and its Patient Registries Initiative, aiming to create a registry framework that involves all stakeholders (registry holders and staff, patient associations, regulatory agencies, and pharmaceuticals companies) (McGettigan et al, 2019;Jonker et al, 2021;Jonker et al, 2017).…”